BioSpace News Archive

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

SwanBio Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead candidate, SBT101.

Frequency Therapeutics, Inc. today announced business updates and financial results for the fourth quarter and full year ended December 31, 2021.

Avinger, Inc. today announced that it will release its financial results for the fourth quarter and full year 2021 after the close of trading on Tuesday, March 22, 2021.

PDS Biotechnology Corporation today announced that the National Cancer Institute (NCI) has achieved the intended enrollment objective of 30 patients in the checkpoint inhibitor (CPI).

Ascletis Pharma Inc. announces the business update on its oral double prodrug ASC10 against Coronavirus Disease 2019.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced today at HIMSS22 that the latest Philips Capsule Surveillance solution has received 510(k) market clearance from the U.S. Food & Drug Administration (FDA), paving the way for widespread deployment across healthcare systems in the USA.

ExCellThera Inc. (ExCellThera), announced today that new long-term data from a clinical trial using its lead technology, ECT-001, a cell therapy under clinical development, to treat patients with severe leukemia who lack a suitable donor will be presented at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

Xtant Medical Holdings, Inc. announced that Sean Browne, President and Chief Executive Officer, will present at the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022, at 2:00 p.m. Central Time in Chicago.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three months and twelve months ended December 31, 2021, on Tuesday, March 22, 2022, at 4:30 p.m. (ET).